EGFR and non-small cell lung carcinoma: Although compared to traditional platinum-based combination chemotherapy, EGFR-TKIs provided significant clinical benefits and became a cornerstone treatment strategy for various cancers including NSCLC with EGFR-activating mutations, the low safety profiles of these agents should be acknowledged [80].